Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University
Articles by Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University
The Evolving Treatment Landscape of Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Closing out their discussion on biliary tract cancers, expert panelists share key takeaways and excitement for the evolving treatment paradigm.
Novel Targeted Therapies Under Investigation in Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Comprehensive insight on novel targeted agents under investigation in the setting of biliary tract cancers.
Biliary Tract Cancers: Combination Strategies With Immune Checkpoint Inhibitors
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University An overview on novel treatment strategies in biliary tract cancers combining immune checkpoint inhibitors with various targeted agents.
TOPAZ-1: Chemotherapy + Durvalumab in Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Centering discussion on the TOPAZ-1 trial of chemotherapy in combination with durvalumab, panelists consider how this regimen has impacted clinical practice.
Standard of Care Systemic Therapies for Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Key opinion leaders in the field of biliary tract cancers highlight mainstay systemic therapy regimens within the treatment paradigm.
Role for Liver Transplant in Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University A brief discussion on the continued role of liver transplant in biliary tract cancers and when it is appropriate to consider a patient for this procedure.
Liver-Directed Treatment Strategies in Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University A comprehensive review of liver-directed therapies available to aid in the management of biliary tract cancers.
Biliary Tract Cancers: Surgical and Perioperative Treatment Strategies
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Moving on to identify specific treatment modalities, panelists discuss the surgical and perioperative strategies used to manage biliary tract cancers.
Advent of Molecular Testing in Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Key opinion leaders review the advent of molecular testing in biliary tract cancers and consider its impact on informing treatment decisionmaking.
Optimizing the Staging of Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Focused conversation on the optimal workup and staging of biliary tract cancers within the current paradigm.
Clinical Scenario: Diagnostic Strategies to Identify Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Centering focus on a patient scenario, panelists break down mainstay diagnostic strategies used to identify biliary tract cancers.
Overview on Biliary Tract Cancers and Their Rising Incidence
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Expert panelists open their discussion on biliary tract cancers by identifying various subsets and noting the growing incidence of these diseases.
Advanced Biliary Tract Cancers: Novel Biomarker Strategies
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Closing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.
Novel Agents Being Explored in Advanced Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Expert panelists provide comprehensive insight on novel targeted agents being investigated in advanced biliary tract cancers.
Sequencing Therapy in Patients With Advanced Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD In the context of advanced biliary tract cancers, panelists reflect on the optimal sequencing of agents throughout multiple lines of therapy.
Advanced Biliary Tract Cancers: Managing Immunotherapy-Related Adverse Events
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Expert perspectives on the toxicity profile of immunotherapy agents and how they can be managed in patients being treated for advanced biliary tract cancers.
Advanced BTC: Informing Use of IO Therapy in Specific Patient Populations
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Shared insight on efforts to identify patient subgroups that may benefit more from immunotherapy in the setting of advanced biliary tract cancers.
TOPAZ-1: Durvalumab + Doublet Chemotherapy in Advanced Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Centering their conversation on the TOPAZ-1 clinical trial, expert panelists review the use of IO + chemotherapy in advanced biliary tract cancers.
Advanced Biliary Tract Cancers: First- and Second-Line Chemotherapy
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Focused discussion on chemotherapy treatment options commonplace in patients with advanced or metastatic biliary tract cancers.
An Overview of Systemic Therapy for Advanced Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Shifting their focus to the advanced disease setting, panelists provide a comprehensive overview on systemic treatment modalities used in biliary tract cancers.
Understanding the Role of Adjuvant Therapy in Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Experts provide brief perspective on the use of adjuvant treatment approaches for patients with biliary tract cancers.
What is the Role of Transplant in Early-Stage Biliary Tract Cancers?
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Before closing out their review of early-stage biliary tract cancer treatment options, panelists consider the role of transplant in the setting.
Treatment Options for Early-Stage Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Centering discussion on early-stage biliary tract cancers, expert panelists consider the respective roles of surgery and embolization strategies in this setting.
Guidelines for Molecular Testing in Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Panelists share their perspectives on molecular testing guidelines for patients diagnosed with biliary tract cancers.
Biliary Tract Cancers: Staging and Clinicopathologic Features
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Comprehensive insight on staging biliary tract cancers followed by an overview of molecular testing and targetable clinicopathologic features.
Challenges in Diagnosing Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Expert perspectives on the presentation of biliary tract cancers with specific insight to the challenges inherent in reaching a timely diagnosis.
Incidence and Risk Factors for Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University,Mark Yarchoan, MD Shared insight on the global incidence of biliary tract cancers and which risk factors most impact the likelihood of disease.
An Overview on Biliary Tract Cancers
ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Aiwu Ruth He, MD, PhD,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Mark Yarchoan, MD,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University Opening their discussion on biliary tract cancers, a multidisciplinary panel of experts consider how specific subsets of these malignancies differ from one another.
TOPAZ-1: Chemotherapy + Durvalumab in Biliary Tract Cancers
Advanced BTC: Informing Use of IO Therapy in Specific Patient Populations
Understanding the Role of Adjuvant Therapy in Biliary Tract Cancers
Clinical Scenario: Diagnostic Strategies to Identify Biliary Tract Cancers
TOPAZ-1: Durvalumab + Doublet Chemotherapy in Advanced Biliary Tract Cancers
Overview on Biliary Tract Cancers and Their Rising Incidence